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Abstract
Background: Familial Mediterranean fever is a recessive autoinflammatory disease frequently encountered in 
Armenians, Jews, Arabs and Turks. The MEFV gene is responsible for the disease. It encodes a protein called pyrin/
marenostrin involved in the innate immune system. A large number of clinically diagnosed FMF patients carry only one 
MEFV mutation. This study aims at studying the MEFV gene splicing pattern in heterozygous FMF patients and healthy 
individuals, in an attempt to understand the mechanism underlying the disease in these patients.
Methods: RNA was extracted from peripheral blood leucocytes of 41 FMF patients and 34 healthy individuals. RT-PCR 
was then performed, and the amplified products were migrated on a polyacrylamide electrophoresis gel, characterized 
by gel extraction of the corresponding bands followed by sequencing.
Results: Five novel splicing events were observed in both patients and controls deleting either exons 3, 4 (del34), or 
exons 2, 3, 4 (del234), or exons 2, 3, 4, 5 (del2345) or exon7 (del7) or exons 7 and 8 (del78).
Conclusions: The observation of such qualitative variability in the expression of the MEFV gene suggests a complex 
transcriptional regulation. However, the expression of these novel transcripts in both patients and controls is not in 
favour of a severe pathogenic effect.
Background
Familial Mediterranean fever (FMF) is an autoinflamma-
tory autosomal recessive disease particularly frequent
around the Mediterranean basin. It is characterized by
recurrent bouts of fever and serosal inflammation, the
most severe manifestation of the disease being renal amy-
loidosis [1]. The MEFV gene on chromosome 16p13.3,
responsible for this disease [2,3], is composed of 10
exons. Over 80 MEFV mutations were detected in FMF
patients and registered in the autoinflammatory mutation
database Infevers http://fmf.igh.cnrs.fr/infevers/[4]. Five
of these mutations (M694V, M694I, V726A, M680I and
E148Q) were mostly encountered in the mainly affected
populations, namely Jews, Armenians, Arabs and Turks
[5]. MEFV encodes a 781 amino acids' protein named
pyrin or marenostrin (P/M) that is involved in the inflam-
matory pathways of the innate immune system [6].
Sequence alignment of the protein revealed 6 domains: a
pyrin domain (or PyD), a bZIP basic domain, a B-box zinc
finger domain, a coiled coil domain, 2 nuclear localization
signals domains and a Ret Finger protein (RFP or B30.2)
domain, also known as SPRY domain [7,8].
MEFV is expressed in neutrophils, eosinophils, mono-
cytes [9,10] and to a lesser extent in skin and peritoneal
fibroblasts [11]. Several alternatively spliced MEFV tran-
scripts have been previously described. The first one
(MEFV-d2) was identified in peripheral blood leukocytes
(PBLs) and lacks exon 2 [12]. Diaz et al. characterized 3
other transcripts in synovial fibroblasts from osteoarthri-
tis affected patients, one substituting exon 2a for exon 2
(2a), one with an extra exon corresponding to a sequence
in intron 4 (4a), and one with an extension of exon 8
(8ext) [13]. Moreover, MEFV-d2 and 2a combined with
4a or 8ext to form four other transcripts: Δ2/4a, 2a/4a,
Δ2/8ext and 2a/8ext. The various combinations of 4a and
8ext result in a frameshift leading to putative truncated
proteins [13].
Clinical diagnosis is often confirmed by genetic testing
of the MEFV gene. However, in an important number of
clinically diagnosed FMF patients, only one MEFV muta-
tion was detected by screening of the genomic MEFV
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Page 2 of 5coding sequence [5,14]. In the present study, we exam-
ined the splicing pattern of MEFV in normal and FMF
PBLs, in an attempt to understand the mechanism under-
lying FMF in the clinically diagnosed patients carrying
only one MEFV mutation. A qualitative analysis of MEFV
transcripts was conducted in 41 FMF patients and 34
healthy individuals. Results were compared, and plotted
to the patient genotype data. Our study did not show evi-
dence for any correlation between genotypes and splic-
ing, but revealed 5 novel transcripts which increases the
number of transcripts identified in human leukocytes.
Methods
Human material from FMF patients and controls
This study included 2 series consisting of 41 unrelated
Lebanese FMF patients who fulfilled international diag-
nostic FMF criteria [15] and 34 Lebanese healthy individ-
uals. 36 of the FMF patients had only one identifiable
exonic mutation and 5 patients had 2 mutations (Table 1).
Written consent was obtained from all individuals, and
the work was approved by the Saint Joseph University
ethical committee. Blood was collected into tubes con-
taining heparin, and whole PBLs were purified by lysis of
the red cells with blood lysis buffer according to standard
protocols.
RT-PCR analysis
Total RNAs were extracted from PBLs using the phenol
chloroform method, then retro-transcribed (RT) into
complementary DNA (cDNA) using random primers.
Two sets of Polymerization Chain Reaction (PCR) were
run on the MEFV cDNAs. The 5' amplicon was obtained
with primers 5' AGCCAGATCCAGAGAGCCA 3' in
exon 1 and 5' CCTGTGCAAGATGTCTCCAA 3' in exon
6 and the 3' amplicon with primers 5' TGCAGAG-
GAAGCTGGAGCA 3' in exon 5 and 5' ACCTCCAC-
CTCCCAGTAACGG 3' in exon 10. The amplified
products were migrated on a polyacrylamide gel and
characterized by extraction of the corresponding bands
from the gel then sequencing on an ABI Prism 3130
genetic analyzer.
Results
The studied series were screened for the presence of
splicing events by RT-PCR. Two overlapping fragments
of MEFV cDNA, one from exon 1 to 6, and one from exon
5 to 10, were amplified. Normal transcripts were
detected, in addition to the already described transcript,
MEFV-d2, that was variously expressed (Figure 1).
Five novel alternative splicing events were identified in
both patients and controls. Three of them were observed
from the 5' PCR products which lacked either exons 2 to
4 (del234), exons 2 to 5 (del2345) or exons 3 and 4 (del34)
(Figure 1, left panel). Two other alternative splicing
events were identified in the 3' fragment, one lacking
exon 7 (del7), and one lacking exons 7 and 8 (del78) (Fig-
ure 1, right panel). The deletion boundaries were charac-
terized by sequencing (Figure 2). This revealed that the
splicing events derived from the MEFV canonical splice-
sites.
The distribution of the 5 new splicing events (Table 1)
showed that del7 and del78 were always found together in
a given individual. del234, del7 and del78 were found in
the majority of the individuals. No correlation was
observed between the new alternative splicing events and
the MEFV exonic mutations, and no significant differ-
ence was elicited between the genetically confirmed FMF
patients, the apparently heterozygous patients and the
healthy individuals.
Discussion
The detection of only one MEFV mutation in clinically
diagnosed FMF patients and the highly variable pheno-
type among FMF patients (even those having the same
MEFV genotype) have always been a subject of concern.
Modifying genes could be a possible explanation for such
observations, as well as the fact that only one MEFV
mutation may cause the disease that could be dominant
with a variable expressivity. Diseases which pattern of
inheritance could be recessive in some families, and dom-
inant in others have already been described [16]. This
work aimed at investigating the expression pattern of the
MEFV gene and trying to relate it to the clinical picture of
the patients.
The study of MEFV transcripts in clinically diagnosed
FMF patients having one or two MEFV mutations and in
healthy controls revealed 5 novel exon skipping events
(del234, del2345, del34, del7 and del78) (Figures 1 and 2),
and one previously reported one (MEFV-d2) [12]. Skip-
ping of exons 2 to 4, 7 and 7-8 were the most frequently
observed events (Table 1).
Molecular events that could cause these alternative
spliced transcripts are still unclear. Sequencing of introns
6 and 7 did not show any relevant sequence variation in
the tested individuals. Furthermore, the absence of corre-
lation between the MEFV point mutations harboured by
the patients and controls, and the observed transcripts
does not support impairment of splicing regulatory ele-
ments that would result in exon skipping [17]. The selec-
tive presence of these transcripts among individuals,
suggests they might be due to modifying genes or to some
external factor such as a reaction to an allergen.
Medlej-Hashim et al. BMC Medical Genetics 2010, 11:87
http://www.biomedcentral.com/1471-2350/11/87
Page 3 of 5
Table 1: MEFV genotypes and splicing events in FMF patients and healthy controls.
Genotype Number of patients 5' Splicing eventsa 3' Splicing eventsa
del34 del234 del2345 del7 del78
Genetically confirmed patients
p.[M694V]+[=] 1 + + +
1
p.[M694I]+[=] 1 + +
p.[M680I]+[=] 1 + + + +
p.[V726A] +[=] 1 + +
Heterozygous patients





p.[M694I]+[?] 1 + + +
1 +




2 + + + +
1 + + + +
1 +
p.[M680I]+[?] 1
1 + + +
p.[P369S/R408Q]+[?] 2 + + + +
1 + + +
p.[A744S]+[?] 2








1 + + +
1 + + + +
1 + + + + +
a The + sign indicates the presence of the corresponding splicing event.
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in both controls and FMF patients' PBLs seems not in
favour of a causal effect of these transcripts in the disease
pathogenesis. Previous quantitative studies aiming at cor-
relating disease and MEFV mRNA expression showed
inconsistent results. MEFV transcript levels decreased
significantly in FMF patients as compared to controls in
the initial reports [18,19], but no significant difference
was evidenced in a more recent series [20]. The present
study opens a new trail to be addressed regarding the
FMF pathophysiology in that the patient's phenotype
could be modulated by variations of the different tran-
scripts' ratio. Such a molecular mechanism has been
recently described in cystic fibrosis patients who dis-
played altered regulation of Toll-like Receptor-4 splice
variants [21]. A larger series is warranted to replicate our
findings. Further analyses of the relative amounts of each
transcript are also necessary to confirm or rule out their
role in the pathogenic mechanisms underlying inflamma-
tion in FMF patients.
Conclusions
In conclusion, we identified 5 novel MEFV splicing
events observed in both clinically diagnosed FMF
patients and controls. The observation of such qualitative
variability in the expression of the MEFV gene suggests
that this gene is subjected to a complex transcriptional
and post-transcriptional regulation. The relative produc-
tion of the different transcripts is a possibility that could
modulate the physiopathological aspect of the disease. Competing interests
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